Heron Therapeutics, Inc.
HRTX
$0.40
-$0.05-10.74%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -14.48% | 6.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.48% | 6.22% | |||
| Cost of Revenue | -12.39% | -3.37% | |||
| Gross Profit | -15.69% | 12.68% | |||
| SG&A Expenses | 2.99% | -4.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.65% | -4.15% | |||
| Operating Income | -12,639.47% | 100.93% | |||
| Income Before Tax | -174.58% | 83.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -174.58% | 83.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -174.58% | 83.12% | |||
| EBIT | -12,639.47% | 100.93% | |||
| EBITDA | -836.70% | 116.53% | |||
| EPS Basic | -172.61% | 84.71% | |||
| Normalized Basic EPS | -217.86% | 62.83% | |||
| EPS Diluted | -172.61% | 84.71% | |||
| Normalized Diluted EPS | -217.86% | 62.83% | |||
| Average Basic Shares Outstanding | 0.86% | 10.38% | |||
| Average Diluted Shares Outstanding | 0.86% | 10.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||